Two Drugs, Five Positive Phase 3s and a 2026 BLA: Kodiak’s Pipeline Hits Full Throttle
DENVER, Colo. (247marketnews.com) -- Kodiak Sciences (NASDAQ:KOD) just gave investors a major reason to refocus on its late-stage retina pipeline: both Zenkuda and tabirafusp-ted met primary endpoints in the pivotal Phase 3 DAYBREAK trial in wet age-related macular degeneration (wAMD).
The headline result is Zenkuda, which met its primary vision endpoint with a p-value of 0.0007 and delivered what Kodiak describes as a combination of rapid disease control and sustained retinal drying. Most strikingly, 54% of patients reached a 24-week dosing interval at one year under strict treat-to-dryness retreatment criteria. Zenkuda achieved non-inferior vision gains versus aflibercept, while showing a 0% intraocular inflammation rate in the trial.
That durability could be the commercial story to watch. Retina specialists have long sought therapies that preserve vision while reducing the frequency of injections. David M. Brown, M.D., chief medical officer of Retina Consultants of America, called the results “truly impressive,” noting that more than half of patients maintained a 24-week dosing interval through year one under the study's stringent retreatment approach.
Kodiak now plans to submit a multi-indication biologics license application for Zenkuda in the fourth quarter of 2026, drawing on five positive Phase 3 studies spanning wAMD, diabetic retinopathy and retinal vein occlusion. The company says the planned submission could position Zenkuda for development across several major retinal vascular diseases.
Zenkuda wasn't the only winner, as Kodiak's second investigational therapy, tabirafusp-ted (KSI-501), also met its vision primary endpoint in DAYBREAK, with a p-value of 0.0036, while meeting its anatomical key secondary endpoint with a p-value below 0.0001. Unlike Zenkuda's anti-VEGF approach, tabirafusp-ted is designed to inhibit both VEGF and IL-6, potentially addressing additional inflammatory biology in retinal disease.
That program now moves toward another important test. Kodiak is actively enrolling the Phase 3 ALTO study in diabetic macular edema, where the company is evaluating whether the dual-target approach can demonstrate superiority over aflibercept.
Kodiak isn't done. Its third late-stage asset, KSI-101, is being developed for macular edema secondary to inflammation, with Phase 3 topline data expected in December 2026.
In other words, Monday's DAYBREAK announcement doesn't merely deliver one positive clinical readout. It strengthens a three-asset late-stage pipeline and puts Zenkuda on the regulatory runway while tabirafusp-ted advances into another potentially important Phase 3 indication.
CEO Victor Perlroth said the DAYBREAK results position Kodiak for “the next stage of Kodiak's evolution” as the company prepares for the planned commercialization of Zenkuda.
The next milestones are already visible: Zenkuda's planned fourth-quarter BLA submission, continued enrollment in ALTO for tabirafusp-ted and the December KSI-101 readout. For a precommercial biotech, that's an unusually dense sequence of potential catalysts.
Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.